Press Release

View printer-friendly version << Back
Federal Appeals Court Affirms Dismissal of Class Action Lawsuit

BOSTON, March 12, 2015 /PRNewswire/ -- Columbia Laboratories, Inc. (Nasdaq: CBRX) ("Columbia" or "the Company"), a specialty pharmaceutical company focused on the development of pharmaceuticals for women's health, announced today that the United States Court of Appeals for the Third Circuit affirmed the prior decision of the United States District Court for the District of New Jersey dismissing the securities class action lawsuit, entitled In re Columbia Laboratories, Inc., Securities Litigation, (D.C. No. 2-12-cv-00614) filed against Columbia, Watson Pharmaceuticals, Inc ("Watson"), and various Columbia and Watson executives.

About Columbia Laboratories 
Columbia Laboratories, Inc. has a successful heritage in developing women's health focused pharmaceutical products, including CRINONE® 8% (progesterone gel), that is marketed by Actavis, Inc. in the U.S. and by Merck Serono S.A. in over 60 additional countries worldwide.  Columbia is leveraging its pharmaceutical development, clinical trial manufacturing, and advanced analytical and consulting services to advance an internal pipeline while generating revenue from pharmaceutical industry customers.  For more information, please visit www.columbialabs.com.

CRINONE® is a registered trademark of Actavis, Inc. in the U.S.

Forward Looking Statements 
Safe Harbor Statement Under the Private Securities Litigation Reform Act of 1995: This communication contains forward-looking statements, which statements are usually indicated by the words "may," "will," "plans," "believes," "expects," "anticipates," "potential," "should," or similar expressions, and which are generally not historical in nature. These include all statements relating to expected financial performance and future business or product developments.  Management believes that these forward-looking statements are reasonable as and when made.  However, such forward-looking statements involve known and unknown risks, uncertainties, and other factors that may cause actual results to differ materially from those projected in the forward-looking statements.  Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date on which they are made. These statements are based on management's current expectations and Columbia does not undertake any responsibility to revise or update any forward-looking statements contained herein, except as expressly required by law.  For a discussion of certain risks and uncertainties associated with Columbia's forward-looking statements, please review Columbia's reports filed with the SEC, including, but not limited to, its Annual Report on Form 10-K for the period ended December 31, 2013.  

Contact:
Katja Buhrer
MBS Value Partners
(212) 661-7004
katja.buhrer@mbsvalue.com

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/federal-appeals-court-affirms-dismissal-of-class-action-lawsuit-300049227.html

SOURCE Columbia Laboratories, Inc.